Brought to you by 
Devax stent will use Occam's drug and coating
31 Jul 2015
Executive Summary
Occam International BV will provide coating services to apply its antiproliferative drug Biolimus A9 to a stent designed by Devax Inc. Occam is one of the cardiovascular device affiliates of the Japanese holding company Sun Biomedical Ltd.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Devax stent will use Occam's drug and coating
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice